Core Viewpoint - The U.S. Department of Defense has suggested including companies like Alibaba, Baidu, and BYD on a list of firms that assist the Chinese military, indicating potential scrutiny and implications for U.S. investors [1] Group 1: Companies Mentioned - Alibaba, Baidu, and BYD are identified as companies that may be involved with the Chinese military and are recommended for inclusion in the 1260H list [1] - Other companies mentioned include NewEase, Huahong Semiconductor, SUTENG, WuXi AppTec, and Zhongji Xuchuang, which also meet the criteria for the 1260H list [1] Group 2: Regulatory Context - The 1260H list aims to identify companies operating in the U.S. that are associated with the Chinese military, serving as a warning for U.S. investors despite lacking direct legal enforcement [1] - The letter from Deputy Secretary Stephen Feinberg to congressional leaders highlights the growing concern regarding U.S. investments in companies linked to the Chinese military [1]

格隆汇11月27日丨根据联交所最新权益披露资料显示，2025年11月21日，药明康德(02359.HK)获JPMorgan Chase & Co.以每股均价102.4881港元增持好仓 73.65万股，涉资约7548.34万港元。 增持后，JPMorgan Chase & Co.最新持好仓数目为25,720,236股，持好仓比例由4.89%上升至5.03%。 | 股份代號: | 02359 | | --- | --- | | 上市法國名稱: | 無錫藥明康德新藥開發股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 27/10/2025 - 27/11/2025 | | 麦格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股 每股的平均價 | | | | 持有權益的股份數目 | 佔已發行的 有關事 | | --- | --- | --- | --- | --- | --- | --- | | | 份數目 | 原因 | | | | (請參閱上述 * 註解) 有投票權股 (日 / 月 | | | | | | | | 份自分比 | | | | | | | | 96 1 | ...

Core Viewpoint - The announcement details a change in shareholder equity for WuXi AppTec Co., Ltd., indicating a reduction in the shareholding percentage of the actual controllers and their concerted action parties due to stock dilution and share reduction activities [1][2][3] Group 1: Shareholder Information - The actual controllers of the company are Ge Li, Zhang Chaohui, and Liu Xiaozhong, who control the shareholder entities [1] - The shareholders who signed voting proxies with the actual controllers are also mentioned, indicating a structured governance approach [1] Group 2: Equity Change Details - On October 10, 2025, the company's total share capital increased from 2,965,692,554 shares to 2,983,757,155 shares due to H-share convertible bonds conversion, resulting in a dilution of the shareholding percentage from 18.46% to 18.35% [1] - From November 20 to November 25, 2025, the information disclosure obligor reduced their holdings by 11,827,898 shares, representing 0.40% of the total share capital, decreasing their total shareholding from 547,539,294 shares to 535,711,396 shares, and the percentage from 18.35% to 17.95% [2] Group 3: Compliance and Future Actions - The equity change complies with relevant laws and regulations, does not trigger a mandatory takeover, and will not change the actual control of the company [2][3] - The equity change is attributed to both the increase in total share capital and the execution of a previously disclosed share reduction plan, ensuring adherence to disclosure obligations [3]

（文章来源：证券日报） 证券日报网讯 11月26日晚间，药明康德发布公告称，2025年11月26日，公司收到信息披露义务人发出 的通知，获知其于2025年11月20日至2025年11月25日通过集中竞价方式合计减持公司股份11，827，898 股，占本公告日公司总股本的0.40%。信息披露义务人及与实际控制人签署投票委托书的股东合计持有 公司股份数从547，539，294股减少至535，711，396股，持股比例从18.35%减少至17.95%，权益变动 触及1%刻度。 ...

Group 1 - China Iron & Steel Group disclosed plans for its controlling shareholder to increase its stake in the company by 65 million to 130 million yuan [1][2] - A total of 11 A-share listed companies announced share reductions, including Meixin Technology, Southern Precision, and Huasheng Lithium Electric [1][2] Group 2 - Meixin Technology's shareholders plan to reduce their holdings by no more than 3.57% [2] - Southern Precision's shareholders intend to reduce their holdings by no more than 2.54% [2] - Huasheng Lithium Electric's shareholders plan to reduce their holdings by no more than 0.63% [2] - Other companies such as Bo Technology, Hesheng Co., Jiangbolong, and Zhangjiang Hi-Tech also announced share reductions ranging from 0.50% to 3.06% [2]

智通财经APP获悉，香港联交所最新数据显示，11月21日，摩根大通增持药明康德(02359)73.6509万 股，每股作价102.4881港元，总金额约为7548.34万港元。增持后最新持股数目约为2572.02万股，持股 比例为5.03%。 ...

智通财经APP获悉，香港联交所最新数据显示，11月21日，摩根大通增持药明康德(02359)73.6509万 股，每股作价102.4881港元，总金额约为7548.34万港元。增持后最新持股数目约为2572.02万股，持股 比例为5.03%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年11月26日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-072 关于股东权益变动触及 1%刻度的提示性公告 相关股东保证向公司提供的信息真实、准确、完整，没有虚假记载、误导性陈 ...

Group 1 - JPMorgan's long position in Wuxi AppTec's H-shares increased from 4.89% to 5.03% on November 21, 2025 [1]

证券代码：603259 证券简称：药明康德 公告编号：临 2025-072 关于股东权益变动触及 1%刻度的提示性公告 相关股东保证向公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 公司董事会及全体董事保证公告内容与相关股东提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少√ | | --- | --- | --- | --- | | 权益变动前合计比例 | 18.46% | | | | 权益变动后合计比例 | 17.95% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否√ | | | 是否触发强制要约收购义务 | 是□ | 否√ | | 一、 信息披露义务人及其一致行动人的基本信息 1、身份类别 投资者及其一致行动人的身份 √控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人） □其他______________（请注明） 2、信息披露义务人信息 | 信息披露义务人名称 | | | | | 投资者身份 | | 统一社会信用代码 | ...